Datafin

Data-driven stock analysis platform for global investors.

Sitemap
HomeScreenerValuationSector Analysis
Resources
LibraryDatafin GuideMetric MethodologyValuation MethodologiesFAQPricingWho Is Datafin?Communication
Legal
Privacy PolicyTerms of UseCookie PolicyKVKK NoticeRefund Policy
Data Sources

Financial data sourced from official regulatory filings and verified market data providers. Metrics calculated using GAAP/IFRS standards.

Disclaimer

The analyses and visuals on this site are for informational purposes only and do not constitute investment advice.

Investment decisions involve risk. Verify data independently and consult a licensed advisor when needed.

© 2026 Datafin Financial Data Analysis Systems. All rights reserved.

Last updated: April 2026

MDT FINANCIAL STATEMENTS

Medtronic PLC — balance sheet, income statement and cash flow trends

MDTMedtronic PLC

🇺🇸 USA · US · Healthcare · Medical Devices

Value itDuel
PriceFinancialsPeers

Income Statement

Quarterly progression — trailing-twelve-month values
RevenueNet Income
020 B202120222023202420252026

Profit Funnel

Q2 2026 · TTM
Revenue36.4 B $Gross Profit23.6 B $ · 65%Operating Income6.5 B $ · 18%Pre-tax Income6.1 B $ · 17%Net Income4.8 B $ · 13%

Percentages are relative to revenue.

Key Figures

YoY change
Revenue36.4 B $+8.4%
Gross Profit23.6 B $+7.9%
Operating Income6.5 B $+8.6%
EBITDA9.7 B $+5.4%
Net Income4.8 B $+2.9%

Peer Comparison· Medical Devices

CompanyRev. GrowthGross MarginEBITDA MarginNet Margin
MDT8.4%65.0%26.7%13.2%
SHL-0.3%38.0%19.1%9.1%
PHIA-1.9%45.2%15.4%5.5%
COH2.0%73.0%24.0%14.6%
Industry median7.4%58.9%5.2%-5.7%
CompanyRev. GrowthGross MarginEBITDA MarginNet Margin
MDT8.4%65.0%26.7%13.2%
SYK8.8%63.7%24.4%13.2%
ABT6.6%56.4%24.8%13.9%
BSX17.4%70.4%26.6%17.2%
EW13.8%78.0%22.5%17.3%
GEHC0.8%42.5%17.0%7.5%
Industry median7.4%58.9%5.2%-5.7%

Balance Sheet

Quarterly period-end values
Total AssetsTotal LiabilitiesEquity
050 B100 B202120222023202420252026

Capital Structure

Q2 2026
Total Assets93 B
  • Equity49.5 B $54%
  • Current Liabilities11.7 B $13%
  • Long-term Liabilities31.3 B $34%

Key Figures

YoY change
Total Assets93 B $+1.5%
Total Liabilities43 B $-1.1%
Total Equity49.5 B $+3.0%
Cash & ST Investments9.2 B $+2.8%
Total Debt28 B $-1.9%
Net Debt26 B $-1.1%

Peer Comparison· Medical Devices

CompanyCurrent RatioDebt/EquityNetDebt/EBITDAEquity/Assets
MDT2.1356.5%1.9353.2%
SHL1.1084.1%3.0440.6%
PHIA1.3271.1%2.0341.8%
COH2.4622.1%0.4269.4%
Industry median3.2844.7%0.8249.7%
CompanyCurrent RatioDebt/EquityNetDebt/EBITDAEquity/Assets
MDT2.1356.5%1.9353.2%
SYK2.1166.3%1.9949.6%
ABT1.3965.4%2.3947.1%
BSX1.9042.6%1.7358.3%
EW4.426.8%-2.0977.5%
GEHC1.1799.1%2.4428.7%
Industry median3.2844.7%0.8249.7%

Cash Flow Statement

Quarterly progression — trailing-twelve-month values
Operating Cash FlowCapital ExpendituresFree Cash Flow
02.5 B5 B7.5 B202120222023202420252026

Cash Flow Bridge

Q2 2026 · TTM
02.5 B5 B7.5 B7.3 B $Operating-2.9 B $Investing-4.8 B $Financing-355 M $Net Change

Key Figures

YoY change
Operating Cash Flow7.3 B $+4.1%
Capital Expenditures1.9 B $+2.4%
Free Cash Flow5.4 B $+4.6%
Dividends Paid-3.6 B $-201.4%

Peer Comparison· Medical Devices

CompanyCF MarginFCF MarginCapEx RatioCF/Net Income
MDT20.2%14.9%5.2%152.7%
SHL12.2%8.7%3.5%134.0%
PHIA13.0%10.8%2.2%236.4%
COH11.2%8.5%2.7%76.6%
Industry median7.2%1.5%4.1%76.6%
CompanyCF MarginFCF MarginCapEx RatioCF/Net Income
MDT20.2%14.9%5.2%152.7%
SYK21.3%18.1%3.2%161.1%
ABT21.0%16.3%4.6%150.8%
BSX21.1%16.7%4.4%122.2%
EW21.6%17.3%4.3%124.3%
GEHC10.2%7.6%2.5%134.8%
Industry median7.2%1.5%4.1%76.6%

Amounts are in the company’s reporting currency. Peer comparison tables use ratio-based metrics so currency differences do not distort the picture.

Go deeper on MDT

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. Price data as of Jul 6, 26. This content is for informational purposes only and is not investment advice.